Integrated Solutions to Maintain Program Compliance
There are many challenges organizations face when maintaining a compliant 340B Drug Pricing Program. At RxStrategies, we specialize in delivering integrated solutions to assist implementation and compliance. Split Billing Provides end-to-end 340B program management and addresses its complexity by reviewing all prescription activity to flag eligible 340B dispenses. CompliancePlus Streamlines workflow, quickly indemnifies…
Stay Ahead of the Game at NACHC’s P&I 2018!
March 14-17, RxStrategies team members Rhodie Smith and Justin Rolling will be in Washington, D.C. for the National Association of Community Health Centers’ (NACHC) 2018 Policy and Issues Forum. Here, industry leaders will gather to offer unique insight to Members of Congress while offering solutions to current program regulations and legislative issues. Stay ahead of…
Clinical Insights: February 13, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Biktarvy® (bictegravir, emtricitabine and tenofovir alafenamide) – February 7, 2018 – Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy®…
Make Your Appointment Now!
The 340B Coalition Winter Conference in San Diego, California is coming up in exactly two weeks! Don’t forget to make your appointment with our team at RxStrategies to discuss solutions to support program compliance and view our 340B CompliancePlus Demo or Dashboard Analytics Demo. Schedule a demo for the conference » Visit Booth #227/326 at…
Clinical Insights: February 5, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval FirvanqTM (vancomycin hydrochloride) – January 29, 2018 – CutisPharma announced that the U.S. Food and Drug Administration (FDA) has approved Firvanq™ (vancomycin hydrochloride) for oral solution, for the…
Get Ready for the 340B Coalition Winter Conference
The 340B Coalition Winter Conference this year takes place during the 25th year of the 340B Program. On February 21-23 in San Diego, California, industry leaders will meet to discuss the latest issues in the program, from regulations and legislative activity to drug prices and government studies. Be sure to stop by Booth #227/326 at…
Clinical Insights: January 22, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval BalcoltraTM (levonorgestrel and ethinyl estradiol and ferrous bisglycinate) – January 19, 2018 – Avion Pharmaceuticals, LLC, received approval of its new drug application (NDA) for the oral contraceptive…
Clinical Insights: January 15, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval No new updates. New Formulation Approval No new updates. New Indication Approval Lynparza® (olaparib) – January 12, 2018 – The Food and Drug Administration…
Join Us at the 340B Coalition Winter Conference!
Join the RxStrategies team at the 340B Coalition Winter Conference in San Diego, California February 21-23. Here, your team can stay up to date on the latest news, trends and regulations in the 340B program to best maintain compliance. We look forward to connecting with industry leaders while gaining insight on 340B happenings and issues…
Maintain 340B Program Compliance in 2018
RxStrategies works with Covered Entities to provide an integrated approach to streamline the delivery of quality care, while maximizing savings and meeting the regulatory challenges associated with 340B program management. RxStrategies’ 340B solutions are key to a comprehensive and compliant 340B program. RxStrategies’ CompliancePlus Audit Solution (Self-Audit Portal) Implement internal processes, controls and protocols that…
Clinical Insights: January 2, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Lumify™ (brimonidine tartrate) – New OTC Drug Approval – December 22, 2017 – Bausch + Lomb, a leading global eye health company and wholly owned subsidiary…
Maintain a Compliant 340B Program in Your Hospital
Through RxStrategies’ hospital-focused services, hospitals can manage and track grant funded subsidies, manage 340B product purchases and inventory, participate in P&T committees, manage pharmacies, receive consulting services to improve financial, operational and strategic management and more. The comprehensive solutions that allow hospitals to maintain a compliant 340B program include: Split Billing – Addresses the complexity…